FOLR1 and neoplasm: Farletuzumab (MORab003; Morphotek, Inc.), the first anti-FRα monoclonal antibody, exhibited anti-tumor activities potentially via inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and persistent tumor cell autophagy leading to reduced cell proliferation and inhibition of the Lyn kinase signaling pathway (77).